To test the hypothesis that alterations in regulatory regions of the insulin gene occur in a subset of patients with non-insulindependent diabetes mellitus (NIDDM), the promoter region was studied by polymerase chain reaction (PCR) amplification directly from genomic DNA, followed by high-resolution polyacrylamide gel electrophoresis under nondenaturing conditions. By using this method a previously identified HincII polymorphism (GTIGAC to GTTGAG at position -56) in American Blacks was readily detected, indicating that single base changes could be observed. In the course of screening the insulin promoter from 40 American Black subjects with NIDDM, an apparent larger allele was found in two individuals. Both patients were shown to have in addition to a normal allele, a larger allele containing an 8-bp repeat, TGGTCTAA from positions -322 to -315 of the insulin promoter.
Introduction
Structural gene mutations have been observed in a small number of individuals with non-insulin-dependent diabetes mellitus (NIDDM)1 (1) . These mutations have been associated with either failure ofconversion ofproinsulin to insulin, orabiologically defective insulin resulting in hyperinsulinemia. Most individuals with NIDDM, however, have insulin resistance and islet (3-cell insulin production is not sufficient to meet enhanced insulin demand (2) . Diminished insulin production would more likely result from decreased transcription of the gene, perhaps due to variations in the insulin promoter region, or to alterations in the genes that regulate transcription of the insulin gene. These transcriptional mutations, if they exist, would be difficult to detect since human islet tissue is not readily available for analysis. Because DNA is easily obtained from subjects with NIDDM, a number of studies have used DNA polymorphisms at the insulin locus to evaluate this possibility.
A hypervariable region ofDNA, composed ofvariable numbers oftandem repeats resulting in many different sized alleles, is located 375 base pairs (bp) upstream from the transcription initiation site of the insulin gene (3) . Initial reports of a positive association of a large class 3 allele with NIDDM were not confirmed in later studies oflarger racially uniform populations (see reference 4 for review). Linkage analysis in families with maturity onset diabetes ofthe young (5, 6) , the autosomal dominant subtype of NIDDM, and in more typical Northern European Caucasian (7) and American Black (8) NIDDM families, concluded that there was no linkage ofthe insulin gene and NIDDM, and that insulin gene defects are not a major factor predisposing to NIDDM. If the disease were polygenic, however, this interpretation may not be correct.
Evidence has been presented that NIDDM is a complex metabolic disorder unlikely to be the result of a single gene defect (9, 10) . Because ofthe limitations ofrestriction fragment length polymorphism RFLP analysis in populations and linkage analysis in families when considering polygenic and multifactorial diseases such as NIDDM (1 1), the current study was undertaken to evaluate insulin genes directly at the genomic 1 . Abbreviations used in this paper: NIDDM, non-insulin-dependent diabetes mellitus; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformational polymorphism.
level. Two new techniques made this analysis possible. The first consists of amplification of specific regions of the insulin gene directly from genomic DNA by the polymerase chain reaction (PCR), followed by separation of the amplified alleles by a highly sensitive electrophoretic method (12, 13) . This method involves incorporation of labeled primers into the amplified DNA fragment during PCR, followed by denaturation of the two strands, and electrophoresis on nondenaturing gels. The mobility ofthe fragments under these conditions is determined by base composition as well as size (single-strand conformational polymorphism [ (14) . NIDDM was defined as described (14) by this group. All Washington University patients with NIDDM were identified by personal history and medical records, and plasma glucose was measured on the sample obtained for DNA. Control subjects were defined as patients > 10 Mg of an insulin-luciferase fusion plasmid plus 10 Mag of salmon DNA carrier (21) . After an overnight incubation in 5% C02, cells were shocked for 2 min with 20% glycerol in DME, washed, and refed. Cells were harvested in 700 Ml of 50 mM Tris-2 (N-morpholino)ethane sulfonic acid (MES) (pH 7.8), 1 mM DTT, 1% Triton X-100, 48 hrs after glycerol shock. Luciferase activity was assayed using a Monolight model 2010 instrument (Analytical Luminescence Laboratory, San Diego, CA), primed with I mM D-luciferin, and integrating light units over 10 s. Reactions (300 Ml) contained 50 mM Tris-MES (pH 7.8), 10 among identical plates within an experiment averaged < 10% (see Table II) . Because of the inherent reproducibility of these results, the relatively low signals, and the possibility ofinterference from inclusion of other plasmids, additional plasmids based on another reporter system for internal standardization of transfection efficiency were not included.
Luciferase reporter plasmids. Luciferase plasmids are derivatives of pSV2A A5'L (22) , with the insulin promoters replacing the SV40 sequences located 5' to the luciferase gene. Insulin promoter sequences are from -366 to +42 and are derived from either the normal allele or the allele containing the 8-bp repeat.
Clinical studies. Oral glucose tolerance tests were performed with 75 g of glucose according to a standard protocol. Hyperglycemic clamps were performed to assess the insulin response to a constant plasma glucose as previously described (23) . Plasma glucose concentration was measured by an automated glucose oxidase method (Beckman Instruments, Inc., Fullerton, CA). Serum insulin concentration was measured by radioimmunoassay.
Statistical analysis. All 
Results
Confirmation that SSCP can detect single base changes in the insulin promoter. To confirm that PCR amplification of the promoter region of the insulin gene and electrophoresis by SSCP would permit detection of differences, a known polymorphism was first studied. A HinclI site at positions -61 to -56 (GTTGAC) had been shown to be absent in 40% ofAmerican Blacks (24) . We sequenced the promoter region directly from genomic DNA of several individuals previously typed at this locus, and determined that HincIH minus alleles had the sequence GTTGAG. PCR amplification of a number of unrelated individual with 32P 5'-end-labeled primer 7096(A) at position -183 and reverse primer 10594(B) at position +42, indicated in Fig. 1 , and electrophoresis under SSCP conditions resulted in clearly identifiable alleles positive or negative for the HincIH site (Fig. 2) .
A variant ofthe insulin promoter, detected by screening with PCR-SSCP. Analysis of the insulin promoter from -183 to +42 of 20 by PCR amplification using primers E and D (Fig. 1 ) from genomic DNA, followed by electrophoresis on a 4% NuSieve (3:1) agarose gel in TBE buffer, and stained with ethidium bromide. Individuals in lanes 1, 2, 6, and 7 have one normal and one larger allele, while those in lanes 3-5 and 8 are homozygous for normal alleles.
TGGTCTAA was repeated in tandem in the larger allele. This same 8-bp repeat was present in other patients, as confirmed by sequencing a variant allele from another American Black NIDDM patient, and a Mauritius Creole patient with NIDDM (see below).
Frequency of the variant allele in three racial groups. To determine the frequency of the variant allele in populations, a more rapid analytical method was devised. Knowing that the variant was an 8-bp larger allele, we PCR-amplified a relatively small fragment ofthe insulin promoter (142 bp) with primers E and D (Fig. 1) , and were able to separate large and small alleles on a 4% agarose (NuSieve) gel as shown in Fig. 5 . This sensitive and more rapid screening method enabled us to evaluate the promoter region from 100 nondiabetic American Black individuals, and an equal number with NIDDM. As shown in Table I, the variant was present in five patients with NIDDM and one nondiabetic subject (P = 0.24).
Next the presence of variant alleles was evaluated in 35 Caucasian NIDDM patients and 40 Pima Indians, and none were found. Mauritius Creoles, like American Blacks, are African descendants with partial European Caucasian admixture, and with a high prevalence ofNIDDM (14) . We had the opportunity to determine the frequency of the variant insulin promoter in a smaller number of Mauritius Creoles, and the variant was identified in three subjects with NIDDM, but in none of the nondiabetic individuals (Table I, NS) .
Clinical evaluation ofthe effects ofthe variant insulin promoter. All five of the NIDDM patients with variant insulin promoters were considered for differences in clinical characteristics. The number ofsubjects was small, and no obvious differences were apparent in age, age of diagnosis of diabetes, body mass index, or insulin requirements. At least three of these patients had a positive family history of NIDDM. One patient (L.M.) had a sister (S.L.) with known diabetes, and four sibs not known to have diabetes, as shown in the pedigree in Fig. 6 . The sister with NIDDM (S.L.) did not have a variant insulin promoter, and thus in this family the insulin promoter variant was not necessary for diabetes. We had the opportunity to study three of the reported nondiabetic sibs (W.L., J.L., and L.P.).
The results of a 3-h oral glucose tolerance test in the three reported nondiabetic sibs ofthe proband are shown in Table II . The sister (L.P.), positive for the variant promoter, was found to have overt NIDDM, with a fasting plasma glucose of 302 mg/dl, and a poor insulin secretory response. The two brothers, one with two normal alleles (W.L.), and the other with a normal and variant insulin promoter (J.L.), showed virtually identical glucose responses, diagnosed as glucose intolerant by crite- riod was 60% greater at similar mean serum insulin concentrations (61 vs. 59 ,uU/ml). Promoter activity assay. To determine whether the presence of the 8-bp tandem repeat within the promoter region conferred different transcriptional activity, a reporter gene assay was developed. Both normal and insert-containing insulin proinoters (from -366 to +42) were subcloned upstream ofthe firefly-luciferase coding region, and these fusion gene plasmids transfected into mouse (3TC 1) and hamster (HIT) insulinoma cells. Transient expression of these chimeric genes in both cell lines revealed that the variant insulin promoter had < 50% of the promoter activity of the normal allele (Table II) .
Discussion
Direct genomic analysis of the insulin gene promoter from NIDDM patients revealed a previously undescribed 8-bp repeat, TGGTCTAA, 315 bp upstream of the start of transcription of the gene. This represents the first variant insulin promoter described. The current studies defined the frequencies of the variant in four racial groups, and addressed the possible biological and clinical consequences ofthe variant on carbohydrate metabolism. The strategies used were (a) to examine clinical phenotypes, (b) perform linkage analysis in a family, along with metabolic studies on selected members, (c) compare the frequencies of the variant in populations of NIDDM patients vs. controls, and (d) assess promoter activity by transient expression in cultured insulinoma cells.
The clinical consequences of the variant insulin promoter are not clear from examination ofthe phenotypes. As only one affected allele was present in all subjects where the variant was detected, a modest effect on insulin gene transcription may have little effect, given that transcription from the normal promoter should be unaffected. The capacity to produce insulin might be altered, however, and manifested perhaps only in obese individuals with higher insulin requirements. There were no obvious differences in phenotypes of the five American Black NIDDM patients with the variant allele however.
As one of these patients had a family available for analysis, we had the opportunity to do linkage analysis and observe the possible clinical consequences ofthe variant (Fig. 6 ). This family appeared to have other genes and/or factors predisposing to NIDDM, in that one sister (S.L.) of the proband (L.W.) had NIDDM without the variant insulin promoter allele. A second sister with a variant promoter (L.P.) was found on testing to be diabetic. While this complicates the analysis, this same problem may be encountered in most families with NIDDM, ifthis disorder is polygenic. We attempted to assess insulin production in the two brothers, one with and the other without the variant promoter, by oral glucose tolerance tests and hyperglycemic glucose clamps. During the glucose tolerance tests, both appeared to be glucose intolerant by standard criteria. As the relationship between insulin sensitivity and p3-cell function is complex and difficult to interpret, the brothers were further assessed by hyperglycemic clamps with a fixed glucose challenge. Although there were minor differences in early insulin responses, overall the responses were comparable. It has never been easy to assess insulin producing capacity in vivo (25) . Both brothers are lean, whereas the diabetic sisters are obese. One might speculate that obesity and genes which promote insulin resistance may be necessary to uncover defects in insulin production. These hypotheses are difficult to test in humans, but have been addressed in experimental animal models (26, 27 The variant insulin promoter appeared to occur more frequently in a population of American Black NIDDM patients relative to nondiabetic controls (5% vs. 1%, (Table II) . Both HIT and OTC 1 cells have been widely used to study expression of insulin genes (29) (30) (31) , but these cells are imperfect models ofregulated expression, being defective in insulin responses to glucose (18, 20) . In this regard, HIT and OTCI cells were cultured in 5, 16, and 25 mM glucose for 48 h after transfections, and the results with the normal and variant promoters did not differ from those described in Table  II . Nonetheless, the differences observed between the activities of normal and variant promoters in both cell types are highly suggestive, and would encourage more definitive studies in vivo using transgenic technology, as well as in cultured insulinoma cells engineered to respond more physiologically to glucose stimulation. In this respect the relationships between the effects of the variant insulin promoter on insulin production and glucose-stimulated insulin secretion in the patients may be more readily appreciated.
The human insulin promoter is transcriptionally active in rodent insulinoma cells (29) (30) (31) and in transgenic mice (32, 33 ). An insulin promoter-chloramphenicol acetyltransferase reporter transfection experiment showed that 879 bp of 5'-flanking DNA conferred tissue specific expression in insulinoma cells, whereas only sequences up to -258 were necessary for full promoter activity (31) . Sequence specific binding of transcription factors was recently demonstrated with nuclear extracts from rat insulinoma cells (29, 30) . Gel retardation and methylation-interference assays revealed specific binding with high affinity to two regions of the human insulin promoter (nucleotides -217 to -210, and -84 to -77), and to a third region (-320 to -313) with low affinity. The consensus sequence for high-affinity binding was C(T/C)CTAATG, while the sequence at the low affinity site -320 to -313 is GTCTAATG, differing only in the G/C at -320. The sequence of the insert variant, TGGTCTAATGGTCTAATG (-330 to -313) contains two ofthe low-affinity transcription factor binding sites, versus one binding site in the normal allele. Gel retardation assays with oligonucleotides containing the repeat region showed additional high molecular weight retarded species relative to that with the normal allele (Andrew Clark and Kevin Docherty, unpublished observations). Whether these differences correspond to differences in transcription of the insulin gene in vivo, however, has not been determined.
Previous studies of the insulin gene in populations of subjects and in families with NIDDM led to the conclusion that this locus did not contribute in a major way to the inherited risk for NIDDM in any racial group (4, 5, 7, 8) . The results of the current study at least partially explain failure to find an association of this locus with NIDDM in American Blacks. In the current study screening the promoter region of 100 NIDDM patients by direct genomic analysis revealed a variant in a relatively small number (5%) which may contribute to the The clinical significance ofthe presence ofa variant insulin promoter is that it may serve as a genetic marker for NIDDM in Blacks. The observations of the presence of the variant in 1 of 100 nondiabetic American Black individuals, and the absence of the variant in 95 of 100 NIDDM patients, are entirely consistent with predictions in a multifactorial disease (34) . A single gene defect is neither sufficient, nor necessary for the occurrence ofthe disease. It might be mentioned in this context that uncommon variations of potential but unproven significance have also been described in the insulin receptor (35) and muscle/adipose tissue glucose transporter (GLUT-4) (36) genes of NIDDM subjects. For the insulin gene, the frequency of the variant in Mauritius Creoles and American Blacks suggests there may be an association with NIDDM. These data, along with the suggestion that the variant has diminished promoter activity in cultured insulinoma cells, suggest that the variant insulin promoter increases the risk ofdeveloping NIDDM, perhaps through impaired insulin biosynthesis at the transcriptional level. This hypothesis remains to be tested.
